La promesse des composes donneurs de NO dans les therapies cellulaires

Expert Opinion on Investigational Drugs. 2007 Jan;16(1):33-43

Nitric oxide: emerging concepts about its use in cell-based therapies

Brunelli S, Rovere-Querini P, Sciorati C, Manfredi AA, Clementi E.
University of Milano-Bicocca, Department of Experimental, Environmental Medicine and Medical Biotechnology, 20052 Monza, Italy.

Regenerative medicine is an emerging clinical discipline in which cell-based therapies are used to restore the functions of damaged or defective tissues and organs. Along with the well-established use of cells derived from bone marrow or pancreatic islets, novel approaches of cell therapy have recently emerged that appear particularly promising; that is, those using cell-based vaccines and stem cells. This review focuses on the recent developments of these experimental therapeutic approaches and their drawbacks, with specific focus on dendritic cell vaccines in tumours and mesoangioblasts in muscular dystrophies. The authors discuss how the unique properties of a gaseous messenger, NO, may be exploited to overcome some of the drawbacks of these cell-based approaches in combined therapies based on NO-releasing drugs and cell delivery.

Source : PMID: 17155852 [PubMed - in process]

1 commentaire:

Anonyme a dit…

intéressant, cela démontre la réactivité de nicox par rapport à l'émergence des nouvelles thérapies géniques!

Mais ne s'éloigne-ton pas de l'expertise initiale de nicox qui est de greffer du no sur des molécules chimiques?

peut-être cela ouvrira-t-il la voie vers de nouvelles collaborations avec des pharmas moins "traditionnelles" comme amgen ou genentech?

(simples remarques d'un actionnaire de base, sans connaissance scientifique!)